Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Thermo Fisher Scientific; GenomeDx Biosciences; Provista; and More

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said this week that its board of directors has declared a quarterly cash dividend of $.15 per share. The dividend will be paid on Oct. 17 to shareholders of record as of Sept. 15. The board has also authorized the repurchase of $1.5 billion of common stock.


GenomeDx Biosciences announced this week that it has received laboratory accreditation from the College of American Pathologists, based on the results of a recent on-site inspection. The company uses its own Decipher GRID genomics database for urologic cancer research to analyze genomic data, and develops and commercializes clinical tests such as its Decipher Biopsy and Decipher Post-Op prostate cancer genomic tests.


Provista Diagnostics announced this week that it has signed 13 agreements with various third-party administrator networks to cover its Videssa Breast protein-based early breast cancer detection blood test. These networks process insurance claims and specific aspects of employee benefit plans, and also act as providers of healthcare services to plan members.


Eastern Biotech said this week it has collaborated with Fulgent Diagnostics to launch its Comprehensive Cancer Panel in the Middle East. The panel analyzes 122 genes associated with the most common hereditary cancer syndromes that involve various cancers including breast, colorectal, endometrial, fanconi anemia, gastric, hematologic malignancy, melanoma, nervous system and brain, ovarian, pancreatic, paraganglioma-pheochromocytoma, prostate, renal and urinary, sarcoma, and thyroid.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.